GUEST: Jason Lewis, New York
In this episode we discuss and learn about new PSMA-binding ligands with 161Tb, their biodistribution, dosimetry, preclinical therapy, and their comparison with conventional PSMA ligands. Our guest is one of the leading scientists in radiochemistry for cancer detection and therapy, the wonderful Jason Lewis.

We talk about the importance of using 161Tb - this novel radionuclide for radioligand therapy - and its favorable decay characteristics as compared to 177Lu. We learn about the added value of the emission of Auger electrons which can effectively eliminate micro-metastasis and when combined with ibuprofen-based PSMA ligands offering albumin-binding properties, tumor uptake and therapeutic efficacy are significantly boosted.

Besides this fascinating science, don't miss some very important advice from a very successful scientist in a very competitive environment about work-life balance, prioritising expectations and goals - just never forget to "smell the roses"…

Selected Publication: Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy. Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller. Journal of Nuclear Medicine Jul 2023, jnumed.123.265524; DOI: 10.2967/jnumed.123.265524
https://jnm.snmjournals.org/content/early/2023/07/13/jnumed.123.265524

Further information on the European Society for Molecular Imaging:
https://e-smi.eu/
Contact: office@e-smi.eu